RXRA and urinary bladder cancer: However, the PPARγ Q286E mutation found in bladder cancer increased PPARγ transactivation by inducing the active conformation, favoring the recruitment of RXRα and co-activators without ligand binding (Figure 2, Figure 3, Figure 4 and Figure 5).